Literature DB >> 10975960

Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection.

R Colven1, R D Harrington, D H Spach, C J Cohen, T M Hooton.   

Abstract

BACKGROUND: Although viral rebound follows cessation of suppressive antiretroviral therapy in chronic HIV infection, a viremic clinical syndrome has not been described.
OBJECTIVE: To describe a retroviral syndrome associated with cessation of effective antiretroviral therapy in chronic HIV infection.
DESIGN: Case reports.
SETTING: Outpatient HIV specialty clinics in Seattle, Washington, and Boston, Massachusetts. PATIENTS: Three patients with chronic HIV infection who discontinued suppressive antiretroviral therapy. MEASUREMENTS: Clinical course, plasma HIV RNA levels, and CD4 cell counts before, during, and after cessation of antiretroviral therapy.
RESULTS: Within 6 weeks after stopping antiretroviral therapy, each patient experienced a clinical illness that resembled a primary HIV syndrome. This coincided with a marked increase in HIV RNA level and, in two of three patients, a decrease in CD4 cell count. After antiretroviral therapy was restarted, each patient's symptoms rapidly resolved in association with resuppression of HIV RNA and increase in CD4 cell count or percentage.
CONCLUSION: A retroviral rebound syndrome similar to that seen in primary HIV syndrome can occur in patients with chronic HIV infection after cessation of suppressive antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975960     DOI: 10.7326/0003-4819-133-6-200009190-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

1.  Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?

Authors:  Diane V Havlir
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  The need for treatment interruption studies and biomarker identification in the search for an HIV cure.

Authors:  Jonathan Z Li; Davey M Smith; John W Mellors
Journal:  AIDS       Date:  2015-07-31       Impact factor: 4.177

Review 3.  Managing comorbidities in patients at the end of life.

Authors:  James Stevenson; Amy P Abernethy; Cathy Miller; David C Currow
Journal:  BMJ       Date:  2004-10-16

Review 4.  Structured treatment interruption in patients infected with HIV: a new approach to therapy.

Authors:  Roy M Gulick
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  "We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry.

Authors:  Karine Dubé; David Evans; Lynda Dee; Laurie Sylla; Jeff Taylor; Asheley Skinner; Bryan J Weiner; Sandra B Greene; Stuart Rennie; Joseph D Tucker
Journal:  AIDS Res Hum Retroviruses       Date:  2017-07-10       Impact factor: 2.205

6.  A flexible nonlinear mixed effects model for HIV viral load rebound after treatment interruption.

Authors:  Rui Wang; Ante Bing; Cathy Wang; Yuchen Hu; Ronald J Bosch; Victor DeGruttola
Journal:  Stat Med       Date:  2020-04-15       Impact factor: 2.373

7.  Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up.

Authors:  S Villar del Saz; O Sued; V Falcó; F Agüero; M Crespo; T Pumarola; A Curran; J M Gatell; A Pahissa; J M Miró; E Ribera
Journal:  J Neurovirol       Date:  2008-11       Impact factor: 2.643

8.  The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.

Authors:  Jonathan Z Li; Behzad Etemad; Hayat Ahmed; Evgenia Aga; Ronald J Bosch; John W Mellors; Daniel R Kuritzkes; Michael M Lederman; Michael Para; Rajesh T Gandhi
Journal:  AIDS       Date:  2016-01-28       Impact factor: 4.177

9.  Retroviral rebound syndrome after treatment discontinuation in a 15 year old girl with HIV attracted through mother-to-child transmission: case report.

Authors:  Vanda Friman; Magnus Gisslén
Journal:  AIDS Res Ther       Date:  2007-02-23       Impact factor: 2.250

Review 10.  Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions.

Authors:  Gina M Graziani; Jonathan B Angel
Journal:  J Int AIDS Soc       Date:  2015-11-09       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.